Differential proteome analysis of conditioned medium of BPH-1 and LNCaP cells

Chinese Medical Journal

Volumn 124, Issue 22, 2011, Pages 3806-3809

  Chen, Wen Zheng ^a,b   Pang, Bo ^c   Yang, Bo ^b   Zhou, Jian Guang ^c   Sun, Ying Hao ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

Conditioned medium; Prostate cancer; Prostate specific antigen; Proteome

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; ALDO KETO REDUCTASE 1A1; BIOLOGICAL MARKER; CREATINE KINASE BB; CYCLOPHILIN A; ENDOPLASMIC RETICULUM PROTEIN 29 PRECURSOR; GLUTATHIONE TRANSFERASE P1; GLYOXALASE 1; HYPOTHETICAL PROTEIN BC004224; ISOCITRATE DEHYDROGENASE ISOENZYME; LAMININ GAMMA2; MESSENGER RNA; PROTEIN; PROTEOME; TRIOSEPHOSPHATE ISOMERASE 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CELL STRAIN BPH 1; CELL STRAIN LNCAP; CONTROLLED STUDY; CULTURE MEDIUM; DATA BASE; DIFFERENTIAL DIAGNOSIS; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PEPTIDE ANALYSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEARCH ENGINE; TWO DIMENSIONAL ELECTROPHORESIS; UPREGULATION;

CELL LINE; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEOME;

EID: 82255173518     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.22.036     Document Type: Article

References (20)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Sun YH. The current situation of prostate cancer research in China. Chin J Urol (Chin) 2004; 25: 77-80.
3. Liu GF. Epidemiological survey of benign prostatic hyperplasia and prostate cancer in China. J Peking Univ (Chin) 2000; 32: 30-33.
4. Hartwell L, Mankoff D, Paulovich A, Ramsey S, Swisher E. Cancer biomarkers: a systems approach. Nat Biotechnol 2006; 24: 905-908.
5. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005; 5: 845-856.
6. Huang LJ, Chen SX, Huang Y, Luo WJ, Jiang HH, Hu QH, et al. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer. Lung Cancer 2006; 54: 87-94.
7. Dombkowski AA, Cukovic D, Novak RF. Secretome analysis of microarray data reveals extracellular events associated with proliferative potential in a cell line model of breast disease. Cancer Lett 2006; 241: 49-58.
8. Wang J, Ying T, Wang H, Shi Z, Li M, He K, et al. 2-D reference map of Bacillus anthracis vaccine strain A16R proteins. Proteomics 2005; 5: 4488-4495.
9. Mikolajczyk SD, Song Y, Wong JR, Matson RS, Rittenhouse HG. Are multiple markers the future of prostate cancer diagnostics? Clin Biochem 2004; 37: 519-528.
10. Andersen H, Jensen ON, Eriksen EF. A proteome study of secreted prostatic factors affecting osteoblastic activity: identification and characterisation of cyclophilin A. Eur J Cancer 2003; 39: 989-995.
11. Calaluce R, Kunkel MW, Watts GS, Schmelz M, Hao J, Barrera J, et al. Laminin-5-mediated gene expression in human prostate carcinoma cells. Mol Carcinog 2001; 30: 119-129.
12. Martin DB, Gifford DR, Wright ME, Keller A, Yi E, Goodlett DR, et al. Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 2004; 64: 347-355.
13. Hubbard MJ, McHugh NJ, Carne DL. Isolation of ERp29, a novel endoplasmic reticulum protein, from rat enamel cells. Eur J Biochem 2000; 267: 1945-1956.
14. Feld RD, van Steirteghem AC, Zweig MH, Weimar GW, Narayana AS, Witte DL. The presence of creatine kinase BB isoenzyme in patients with prostatic cancer. Clin Chim Acta 1980; 100: 267-273.
15. Rehman I, Azzouzi AR, Catto JW, Allen S, Cross SS, Feeley K, et al. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 2004; 64: 1238-1243.
16. Davidson SD, Milanesa DM, Mallouh C, Choudhury MS, Tazaki H, Konno S. A possible regulatory role of glyoxalase I in cell viability of human prostate cancer. Urol Res 2002; 30: 116-121.
17. Montgomerie JZ, Gracy RW, Holshuh HJ, Keyser AJ, Bennett CJ, Schick DG. The 28K protein in urinary bladder, squamous metaplasia and urine is triosephosphate isomerase. Clin Biochem 1997; 30: 613-618.
18. Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res 2002; 8: 2298-2305.
19. Li M, Ittmann MM, Rowley DR, Knowlton AA, Vaid AK, Epner DE. Glutathione S-transferase pi is upregulated in the stromal compartment of hormone independent prostate cancer. Prostate 2003; 56: 98-105.
20. Christopher SA, Diegelman P, Porter CW, Kruger WD. Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res 2002; 62: 6639-6644.